Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.

Trends in cardiovascular medicine - 1 Aug 2009

Khera Amit V, Rader Daniel J

Abstract excerpt

Several high-profile failures of lipid-related therapeutics in clinical trials have led to intense interest in improved discovery and preclinical prioritization of potential targets. The careful study of patients with rare monogenic disorders has played a key role in establishing the causal role of cholesterol in atherosclerosis and highlighting viable drug targets. Systematic efforts to extend the association of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, HDL
Share to Cholesterol, LDL
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Hypolipidemic Agents

Share to Lipid Metabolism

Share to Lipoprotein(a)

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 20211435
DOI: 10.1016/j.tcm.2009.12.003
PMCID: PMC3328807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.PMID 20211435Read ↗

Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants.Semantic proximity Read ↗

Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options.Semantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

A Comprehensive Review of the Genetics of Dyslipidemias and Risk of Atherosclerotic Cardiovascular DiseaseSemantic proximity Read ↗

Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine.Semantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human geneticsSemantic proximity Read ↗

Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.Semantic proximity Read ↗

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial HypercholesterolemiaSemantic proximity Read ↗

Pharmacogenomics of blood lipid regulation.Semantic proximity Read ↗

Coronary Artery Disease Genetics Enlightened by Genome-Wide Association StudiesSemantic proximity Read ↗

Genetic determinants of lipid homeostasis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.